

### IN THE CLAIMS

Please amend the claims as follows:

1-35. (Canceled)

36. (New) An apparatus comprising:

an implantable device including a peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating initially providing a slippery lubricating surface after being exposed to an aqueous substance, and then later providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing tissue ingrowth.

37. (New) The apparatus of claim 36, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

38. (New) The apparatus of claim 37, in which a distal portion of the lead is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein.

39. (New) The apparatus of claim 36, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

40. (New) The apparatus of claim 39, in which the non-therapeutic agent includes mannitol.

41. (New) The apparatus of claim 39, in which the non-therapeutic agent includes glycerol.

42. (New) The apparatus of claim 36, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

43. (New) The apparatus of claim 42, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

44. (New) The apparatus of claim 36, in which the coating includes particles disposed in a water-vapor permeable medium.

45. (New) An apparatus comprising:

an implantable device including a peripheral surface that is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing tissue ingrowth..

46. (New) The apparatus of claim 45, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

47. (New) The apparatus of claim 45, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

48. (New) The apparatus of claim 47, in which the non-therapeutic agent includes mannitol.

49. (New) The apparatus of claim 47, in which the non-therapeutic agent includes glycerol.

50. (New) The apparatus of claim 45, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

51. (New) The apparatus of claim 50, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

52. (New) The apparatus of claim 45, in which the coating includes particles disposed in a water-vapor permeable medium.

53. (New) An apparatus comprising:  
an implantable device including a peripheral surface; and  
an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating including a therapeutic agent disposed in a medium that is permeable by water vapor.

54. (New) The apparatus of claim 53, in which the coating provides at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing adhesive but breakable tissue ingrowth.

55. (New) The apparatus of claim 54, in which the coating initially provides a slippery lubricating surface after being exposed to an aqueous substance, and then later provides the at least one of the rough surface and the porous surface after being exposed to the aqueous substance.

56. (New) The apparatus of claim 53, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

57. (New) The apparatus of claim 56, in which a distal portion of the lead is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein.

58. (New) The apparatus of claim 53, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

59. (New) The apparatus of claim 58, in which the non-therapeutic agent includes mannitol.

60. (New) The apparatus of claim 58, in which the non-therapeutic agent includes glycerol.

61. (New) The apparatus of claim 53, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

62. (New) The apparatus of claim 61, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

63. (New) An apparatus comprising:

an implantable device including a peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the coating including two therapeutic agents with different release rates.

64. (New) The apparatus of claim 63, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

65. (New) The apparatus of claim 63, in which the two therapeutic agents include at least one of dexamethasone acetate and dexamethasone sodium phosphate.

66. (New) The apparatus of claim 63, in which the coating further includes at least one of mannitol and glycerol.

67. (New) An apparatus comprising:

an implantable device including a peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the coating including at least one therapeutic agent and at least one lubricating agent.

68. (New) The apparatus of claim 67, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

69. (New) The apparatus of claim 67, in which the at least one therapeutic agent includes dexamethasone.

70. (New) The apparatus of claim 67, in which the at least one therapeutic agent includes dexamethasone sodium phosphate.

71. (New) The apparatus of claim 67, in which the at least one lubricating agent includes mannitol.

72. (New) The apparatus of claim 67, in which the at least one of the rough surface and the porous surface allows enough tissue ingrowth to affix an intravascular lead, and the tissue ingrowth is modified by the at least one therapeutic agent to allow the intravascular lead to be easily intravascularly extracted by breaking the tissue ingrowth.

PRELIMINARY AMENDMENT

Serial Number: 10/608,850

Filing Date: June 24, 2003

Title: IMPLANTABLE LEAD WITH DISSOLVABLE COATING FOR IMPROVED FIXATION AND EXTRACTION

Page 8

Docket No: 279.133US3



Conclusion

Claims 1-35 have been canceled and claims 36-72 are newly added. The Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to the examination and consideration of the above-identified application. The Examiner is invited to telephone Applicant's attorney at (612) 373-6951 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully Submitted,

RONALD W. HEIL, JR. ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6951

Date June 25, 2004 By Suneel Arora  
Suneel Arora  
Reg. No. 42,267

CERTIFICATE UNDER 37 CFR § 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelop addressed to: Commissioner for Patents, MS: Missing Parts, P.O. Box 1450, Alexandria, VA 22313-1450, on this 25 day of June 2004.

Name Lisa Rosarske

Signature Lisa Rosarske